Amy Hankin

658 total citations
28 papers, 210 citations indexed

About

Amy Hankin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Immunology. According to data from OpenAlex, Amy Hankin has authored 28 papers receiving a total of 210 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 9 papers in Immunology. Recurrent topics in Amy Hankin's work include Prostate Cancer Treatment and Research (24 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Immunotherapy and Immune Responses (9 papers). Amy Hankin is often cited by papers focused on Prostate Cancer Treatment and Research (24 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Immunotherapy and Immune Responses (9 papers). Amy Hankin collaborates with scholars based in United States and New Zealand. Amy Hankin's co-authors include Ravi A. Madan, Louis M. Weiner, Michael J. Pishvaian, John L. Marshall, Jonathan R. Brody, Jimmy J. Hwang, Aiwu Ruth He, James L. Gulley, Fatima Karzai and William L. Dahut and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Amy Hankin

26 papers receiving 208 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy Hankin United States	7	161	78	77	58	41	28	210
Azam Ghafoor United States	7	84 0.5×	90 1.2×	59 0.8×	43 0.7×	33 0.8×	15	221
Jinzhi Lai China	7	118 0.7×	37 0.5×	104 1.4×	43 0.7×	70 1.7×	17	223
Lorena Fariñas-Madrid Spain	8	205 1.3×	33 0.4×	91 1.2×	40 0.7×	23 0.6×	24	280
Floriana Camarda Italy	7	136 0.8×	46 0.6×	89 1.2×	18 0.3×	44 1.1×	27	236
Marion Pedrero France	3	135 0.8×	70 0.9×	51 0.7×	65 1.1×	68 1.7×	3	193
Elise Ballot France	7	148 0.9×	50 0.6×	61 0.8×	130 2.2×	35 0.9×	10	256
Lijuan Ding China	8	158 1.0×	81 1.0×	45 0.6×	38 0.7×	24 0.6×	24	227
James J. Saller United States	8	142 0.9×	75 1.0×	119 1.5×	47 0.8×	46 1.1×	25	275
Weiqing Lu China	5	96 0.6×	38 0.5×	185 2.4×	48 0.8×	104 2.5×	8	278
Stephanie O. Dudzinski United States	5	126 0.8×	46 0.6×	68 0.9×	132 2.3×	48 1.2×	12	268

Countries citing papers authored by Amy Hankin

Since Specialization

Citations

This map shows the geographic impact of Amy Hankin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Hankin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Hankin more than expected).

Fields of papers citing papers by Amy Hankin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Hankin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Hankin. The network helps show where Amy Hankin may publish in the future.

Co-authorship network of co-authors of Amy Hankin

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Hankin. A scholar is included among the top collaborators of Amy Hankin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Hankin. Amy Hankin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Madan, Ravi A., Melissa L. Abel, Esther Mena, et al.. (2025). Prospective monitoring of prostate specific membrane antigen–positive biochemically recurrent prostate cancer (PSMA+ BCR): Preliminary data from 6-month PSMA follow-up.. Journal of Clinical Oncology. 43(16_suppl). 5098–5098.

Redman, Jason M., Ravi A. Madan, Fatima Karzai, et al.. (2024). 1631P Results from the quick efficacy seeking trial (QuEST1) arm combining BN-brachyury (BNVax) + bintrafusp alfa (BA) + nogapendekin alfa inbakicept-pmln (N-803) in castration-resistant prostate cancer (CRPC). Annals of Oncology. 35. S984–S985. 1 indexed citations

Madan, Ravi A., Esther Mena Gonzalez, Jeanny B. Aragon‐Ching, et al.. (2024). 1614P PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT). Annals of Oncology. 35. S974–S975. 1 indexed citations

Madan, Ravi A., Renee N. Donahue, Fatima Karzai, et al.. (2022). 1412P Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 33. S1191–S1191. 1 indexed citations

Atiq, Mohammad, Renee N. Donahue, Fatima Karzai, et al.. (2022). Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer.. Journal of Clinical Oncology. 40(6_suppl). 130–130. 3 indexed citations

Atiq, Mohammad, Shruti U. Gandhy, Fatima Karzai, et al.. (2022). PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology. 40(16_suppl). e17046–e17046. 1 indexed citations

Atiq, Mohammad, Fatima Karzai, Marijo Bilušić, et al.. (2022). Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.. Journal of Clinical Oncology. 40(16_suppl). e17033–e17033. 3 indexed citations

Atiq, Mohammad, Shruti U. Gandhy, Fatima Karzai, et al.. (2021). Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology. 39(15_suppl). e17044–e17044. 1 indexed citations

Lassoued, Wiem, Antonios Papanicolau‐Sengos, Jennifer L. Marté, et al.. (2021). 420 PROSTVAC in combination with nivolumab enhanced immune cell infiltration in prostate cancer. SHILAP Revista de lepidopterología. A450–A450. 3 indexed citations

10.

Madan, Ravi A., Susan F. Slovin, Lauren C. Harshman, et al.. (2020). 681P Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc). Annals of Oncology. 31. S542–S542. 1 indexed citations

11.

Redman, Jason M., Ravi A. Madan, Fatima Karzai, et al.. (2020). 616MO Efficacy of BN-brachyury (BNVax) + bintrafusp alfa (BA) + N-803 in castration-resistant prostate cancer (CRPC): Results from a preliminary analysis of the Quick Efficacy Seeking Trial (QuEST1). Annals of Oncology. 31. S511–S511. 6 indexed citations

12.

Gandhy, Shruti U., Fatima Karzai, Jennifer L. Marté, et al.. (2020). PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide.. Journal of Clinical Oncology. 38(6_suppl). 105–105. 6 indexed citations

13.

Madan, Ravi A., Fatima Karzai, Daniel P. Petrylak, et al.. (2019). A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 37(7_suppl). 173–173. 3 indexed citations

14.

Chen, Gang, Fatima Karzai, Ravi A. Madan, et al.. (2018). CRLX101 plus olaparib in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 36(15_suppl). TPS5096–TPS5096. 1 indexed citations

15.

Pishvaian, Michael J., Rebecca Slack, Wei Jiang, et al.. (2018). A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. Cancer. 124(11). 2337–2346. 54 indexed citations

16.

Madan, Ravi A., Fatima Karzai, Marijo Bilušić, et al.. (2018). Immunotherapy for biochemically recurrent prostate cancer.. Journal of Clinical Oncology. 36(6_suppl). 215–215. 5 indexed citations

17.

Singh, Harbhej, Fatima Karzai, Marc R. Theoret, et al.. (2018). Intermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerability. Annals of Oncology. 29. viii297–viii297. 1 indexed citations

18.

Karzai, Fatima, Ravi A. Madan, Helen Owens, et al.. (2017). Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 35(15_suppl). 5026–5026. 18 indexed citations

19.

Pishvaian, Michael J., Hongkun Wang, Aiwu Ruth He, et al.. (2013). A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology. 31(4_suppl). 147–147. 18 indexed citations

20.

Pishvaian, Michael J., Rebecca Slack, Aiwu Ruth He, et al.. (2011). A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer.. Journal of Clinical Oncology. 29(15_suppl). 3502–3502. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact